# Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer

> **NCT01176552** · PHASE2 · COMPLETED · sponsor: **Kidney Cancer Research Bureau** · enrollment: 35 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** GM-CSF, IFN alpha and IL-2

## Key facts

- **NCT ID:** NCT01176552
- **Lead sponsor:** Kidney Cancer Research Bureau
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2008-09
- **Final completion:** 2010-05
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2010-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01176552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01176552, "Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01176552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*